Loading stock data…
Vyome Holdings, Inc. (HIND)
$2.13-0.03 (-1.39%)
Market ClosedLast close Jun 29
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Vyome Holdings, Inc. in the Healthcare sector is trading at $2.13 with a market capitalization of $16M. Wall Street consensus targets $11.50 (2 analysts), implying a +439.9% move over the next 12 months. The stock is currently near its 52-week low of $1.75, remaining 39.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +439.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q1 2025 | Q4 2024 |
|---|---|---|---|---|---|
| Total Revenue | $31,591↓ | $36,551↑ | $34,627↓ | $198,581↑ | $61,428 |
| Gross Profit | $16,645↓ | $22,066↑ | $18,050↓ | $154,419↑ | $62,761 |
| Operating Income | -$1.13M↑ | -$1.36M↓ | -$868,777↓ | -$198,998↑ | -$256,006 |
| Net Income | -$962,910↑ | -$1.06M↑ | -$8.60M↓ | -$293,974↑ | -$306,557 |
Peer Comparison
JNJUNHPFE
Fundamentals
Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$16.14M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-161.87%
Volume
Today's trading volume
4,873
Recent News
Vyome Holdings Inc (HIND) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ...
Vyome Holdings Inc (HIND) showcases promising clinical progress and a robust cash position, despite a significant net loss driven by merger expenses.
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate
We can readily understand why investors are attracted to unprofitable companies. For example, although...
Vyome to leverage US-India ties to tackle $100B immuno-inflammatory market
Investing.com -- U.S.-India focused clinical-stage pharmaceutical maker Vyome Holdings (Nasdaq: HIND) rang the opening bell at the NASDAQ on Friday, celebrating Indian Independence Day and its trading debut after a reverse merger with ReShape Lifesciences.